Literature DB >> 9029070

Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis.

M E Cudkowicz1, D McKenna-Yasek, P E Sapp, W Chin, B Geller, D L Hayden, D A Schoenfeld, B A Hosler, H R Horvitz, R H Brown.   

Abstract

We registered 366 families in a study of dominantly inherited amyotrophic lateral sclerosis. Two hundred ninety families were screened for mutations in the gene encoding copper-zinc cytosolic superoxide dismutase (SOD1). Mutations were detected in 68 families. The most common SOD1 mutation is an alanine for valine substitution in codon 4 (50%). We present clinical and genetic data concerning 112 families with 395 affected individuals. The clinical characteristics of patients with familial amyotrophic lateral sclerosis arising from SOD1 mutations are similar to those lacking SOD1 defects. Mean age at onset was earlier (Wilcoxon test, p = 0.004) in the SOD1 group (46.9 years [standard deviation, 12.5] vs 50.5 years [11.5] in the non-SOD1 group). Bulbar onset was associated with a later onset age. The presence of either of two mutations, G37R and L38V, predicted an earlier age at onset. Kaplan-Meier plots demonstrated shorter survival in the SOD1 group compared with the non-SOD1 group at early survival times (Wilcoxon test, p = 0.0007). The presence of one mutation, A4V, correlated with shorter survival. G37R, G41D, and G93C mutations predicted longer survival. This information suggests it will be productive to investigate other genetic determinants in amyotrophic lateral sclerosis and to use epidemiological characteristics of the disease to help discern molecular mechanisms of motor neuron cell death.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029070     DOI: 10.1002/ana.410410212

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  115 in total

Review 1.  Introduction to the minireviews series on mitochondrial matters in amyotrophic lateral sclerosis, Lou Gehrig’s disease.

Authors:  George H Sack
Journal:  J Bioenerg Biomembr       Date:  2011-12       Impact factor: 2.945

Review 2.  Programmed cell death in amyotrophic lateral sclerosis.

Authors:  Christelle Guégan; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 3.  Complex genetics of amyotrophic lateral sclerosis.

Authors:  Catherine B Kunst
Journal:  Am J Hum Genet       Date:  2004-10-11       Impact factor: 11.025

Review 4.  Familial Amyotrophic Lateral Sclerosis.

Authors:  Kevin Boylan
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

5.  Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant.

Authors:  L I Bruijn; M F Beal; M W Becher; J B Schulz; P C Wong; D L Price; D W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 6.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 7.  Diagnostic investigation and multidisciplinary management in motor neuron disease.

Authors:  J A Rocha; C Reis; F Simões; J Fonseca; J Mendes Ribeiro
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

Review 8.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

Review 10.  Physical activity and neuroprotection in amyotrophic lateral sclerosis.

Authors:  Mary E McCrate; Brian K Kaspar
Journal:  Neuromolecular Med       Date:  2008-02-20       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.